FDA Stresses Sponsor Responsibility in Decentralized Clinical Trials

FDA is reaffirming support for decentralized clinical trials (DCTs) while making clear that moving trial activities outside traditional research sites does not reduce sponsor accountability, according to new client alert from Crowell & Moring.

In updated guidance, the agency signaled that decentralized elements — such as telehealth visits, home-based care, and remote data collection — can be incorporated into clinical trials when appropriately designed. However, regulators emphasized that these models must be carefully planned, fully documented, and supported by strong oversight systems, the alert notes.

From FDA’s perspective, decentralized approaches must be embedded into the trial protocol from the outset. Sponsors are expected to clearly define how off-site activities will be conducted, who is responsible for each task, and how those activities will be monitored.

The alert says that this includes assigning responsibilities across a broader network of parties, such as investigators, contract research organizations, home health providers, and telemedicine vendors. Sponsors must also ensure that safety reporting, investigational product handling, and participant support remain robust outside the traditional site setting.

The agency underscores that decentralized trial models do not change its expectations around compliance with core regulatory requirements, including protection of study participants and assurance of data integrity.

While DCTs may improve patient access and convenience, FDA’s guidance suggests they introduce additional operational complexity. Sponsors must demonstrate that remote data collection and trial procedures are reliable, verifiable, and consistently executed, according to the alert. That includes ensuring adequate monitoring of off-site activities, maintaining clear documentation, and implementing systems capable of detecting and addressing safety or quality issues in real time.

FDA’s framework points to several practical considerations for companies designing decentralized trials:

• Early identification of which trial activities will occur remotely and how they will be supervised
• Clear allocation of responsibilities among all parties involved in trial execution
• Robust processes for safety monitoring and adverse event reporting outside clinical sites
• Controls for investigational product distribution, handling, and accountability in decentralized settings
• Systems to ensure data quality, traceability, and regulatory compliance

The agency’s bottom line is that decentralization is a permissible operational model, not a regulatory shortcut, the alert points out. Sponsors remain fully responsible for ensuring that trials meet FDA standards regardless of where activities occur.